Objectives. This work was done to determine the role of hypertension treatment in the prevention of disease progression, left ventricular hypertrophy and congestive heart failure.
Before the 1950s, approximately 40% of deaths from hypertension resulted from congestive heart failure (1, 2) . This trend was reversed with the introduction of effective antihypertensive drugs in the 1950s and 1960s and the lowering of blood pressure in large numbers of hypertensive patients. A recent review concluded that the occurrence of heart failure in hypertensive subjects had been dramatically reduced in younger persons and that congestive heart failure onset was delayed by several decades; at present it occurs primarily as a complication of coronary artery disease (3) .
Data on the primary prevention of left ventricular hypertrophy and congestive heart failure have not always been specifically quantified in the major hypertension treatment trials. Analyses have tended to focus on so-called "hard end points" in estimating benefits of treatment--the incidence of strokes and stroke deaths, myocardial infarctions and deaths from myocardial infarction (4, 5) . Prevention of progression from less to more severe hypertensive disease and the prevention of left ventricular hypertrophy and congestive heart failure or reversal of pretreatment left ventricular hypertrophy have not, therefore, often been factored into the benefit equation. For these reasons, most analyses of the clinical trials tend to underestimate benefit of treatment (6) .
Diuretics were used as initial monotherapy or in combination with reserpine, hydralazine or methyldopa in almost all of the clinical trials in the 1960s to 1980s (7) (8) (9) (10) (11) (12) (13) . One early study compared diuretics to beta-adrenergic blocking drugs (14) . In the past 15 years, several large-scale studies have used either diuretics or beta-blockers as initial therapy or compared diuretics to beta-blockers (15) (16) (17) (18) (19) (20) .
Methods
In a previous metaanalysis of hypertension treatment resuits (4), we summarized data on coronary heart disease and stroke end points.
Review of clinical trends, For this overview we reviewed all of the major clinical trials listed in Table 1 to determine the numbers of subjects who progressed from less severe (stage I or II) to more severe hypertension, the degree to which the incidence of congestive heart failure was reduced in treated compared to control or placebo subjects and, where possible, the degree to which left ventricular hypertrophy was prevented.
There were no other long-term trials (more than 6 months in duration) that we were able to identify that contain placebo or control groups or sufficient numbers of subjects (more than 25) to warrant inclusion in our analysis. In addition, the initial Medical Research Council (MRC) trial (14) and the MRC trial in the elderly (17) were omitted from this part of our analysis because neither provided data on the development of congestive heart failure or left ventricular hypertrophy. The trials reviewed differed greatly in size and characteristics of the population studied, but all of them used diuretics either as initial monotherapy or as one of the two first-step treatments. At the time most of these trials were initiated, angiotensinconverting enzyme inhibitors and calcium channel blockers were not available. The majority of subjects in the larger trials were stage I or stage II hypertensives, although in the Veterans Administration and the HDFP trials, there were individuals with more severe degrees of hypertension. Several trials specifically examined the effects of treatment in the elderly, that is, the European Working Party Study (18), Coope and Warrender (20) , the Systolic Hypertension in the Elderly (SHEP) (19) and the Swedish Trial in Old Persons (STOP-Hypertension) (15) . The Australian and HDFP trials also had cohorts of elderly patients (10, 11) . In hypertension treatment studies of the elderly, benefit of treatment (or lack of it) was easier to demonstrate because of the larger numbers of vascular events that occurred over a reasonably short period of time (3 to 5 years) in both treated and control subjects.
Methods of analysis. Data on congestive heart failure and left ventricular hypertrophy were analyzed as follows. We used standard methods for combining information from 2 × 2 tables to perform the statistical overview (21) . We calculated typical odds ratios (which approximate the relative risk, RR) for the incidence of congestive heart failure and left ventricular hypertrophy and calculated 95% confidence intervals. The specific formulas for these risk estimates and the test for statistical significance have been described elsewhere (21) .
Results
Prevention of congestive heart failure. In the original Veterans Administration study of severe hypertensives (7) (with pretreatment diastolic pressures of 115 to 129 mm Hg), there were four cases of congestive heart failure in the nontreated group versus none in the treated group (Table 1) . These patients received triple drug therapy (diuretics, reserpine and hydralazine). In other relatively small studies of patients from the Veterans Administration with moderately severe hypertension (8), 6% to 9% of patients had entered the study with a history of congestive heart failure before randomization. Eleven of 194 patients developed congestive heart failure in the control group, whereas none in the treated group of 186 developed this complication. Nine of the 11 patients who developed congestive heart failure were over 60 years of age. In the U.S. Public Health Service Study (9) , two patients in the placebo group developed congestive heart failure compared to none in the group treated with a diuretic and reserpine. The Australian Trial in Mild Hypertension (11) studied a much larger group of subjects with less severe hypertension and little evidence of pretreatment target organ involvement. The probability of an occurrence of a cardiovascular event was low. Even in a study of this size, with more than 3,000 subjects, it is difficult to demonstrate statistically significant benefits of therapy with a low risk population. There was actually no difference between the small percentage of patients who developed congestive heart failure in the treated compared to the placebo subjects (3 of 1,721 versus 3 of 1,706). In the HDFP study (10), we were unable to find the numbers of subjects who developed congestive heart failure.
The HAPPHY study (16) compared a diuretic to a betablocker but did not include a control or placebo group. A congestive heart failure incidence was reported of 1.8 per 1,000 patient years in the diuretic group and 2.6 per 1,000 patient years in the beta-blocker cohort. These data suggest an increased benefit in the subjects treated with a diuretic, but the difference was not statistically significant. These findings are not included in the present metaanalysis.
Congestive heart failure results in the elderly. Much of the data on the reduction in congestive heart failure comes from the studies of elderly hypertensives. In the SHEP study (19) , treatment included a small dose of a diuretic with a betablocker added if blood pressures were not reduced to goat levels. A high percentage of subjects achieved goal blood pressures on diuretic monotherapy. Congestive heart failure occurred in 56 of 2,365 people in the active treatment group compared to 109 of 2,371 people in the control or placebo group. There was a reduction of more than 50% in congestive heart failure incidence. In the EWPHE study (18) , which also was diuretic based, there was a reduction of 63% in the incidence of congestive heart failure (7 of 416 or 5 per 1,000 patient years in the treated compared to 17 of 424 or 13 per 1,000 patient years). Coope and Warrender (20) reported a decrease of 33% (22 of 419 in the treated group compared to 36 of 465 in the control group). The STOP-Hypertension study (15) reported 39 patients who developed congestive heart failure in the placebo group compared to 19 in the treated group, a reduction of 51%. This trial compared several different beta-blockers to a diuretic as well as a placebo. There are no data available on the specific incidence of congestive heart failure with different medications.
When all of the studies are combined, a large and statistically significant reduction of 52% was found in the occurrence of congestive heart failure in the hypertension treatment trials in treated compared to control or placebo subjects (relative risk [RR] 0.48, 95% confidence interval [CI] 0.38 to 0.59). As noted, most of these trials used diuretics as initial therapy.
Overall, 112 individuals assigned to active treatment developed congestive heart failure compared to 240 in the control group. The numbers of events that occurred in the treated and comparison groups and the relative risk estimates are shown in Table 1 . Data on the incidence of congestive heart failure were available in 12 of the 15 trials reviewed.
Prevention of left ventrieular hypertrophy. Data were available in only four of the trials reviewed (Table 2 ).
In the HDFP study, new onset left ventricular hypertrophy by ECG criteria developed in only 127 subjects treated in the stepped-care (SC) or special treatment groups compared to 183 in the RC (regular care) group (22) . (This trial was not placebo controlled; patients in the RC group were treated with some blood pressure-lowering medication. Difference between groups may have actually been greater had one group received a placebo). Left ventricular hypertrophy was present in almost 45% of subjects in both the SC and the RC groups at baseline. Medication in the HDFP study included the use of chlorthalidone, 25 to 100 mg with or without a potassium-sparing agent, reserpine, 0.1 to 0.25 mg, or methyldopa and hydralazine, 30 to 200 mg/day when necessary.
Overall, a total of 140 subjects developed left ventricular hypertrophy in the treated compared to 216 in the control or placebo cohorts. For left ventricular hypertrophy, the RR was 0.650 (a reduction of 35%) and also statistically significant (95% CI 0.52 to 0.79).
Prevention of progression of less severe to more severe hypertension. Table 3 summarizes data available from the clinical trials on the numbers of patients who progressed from less to more severe hypertension, defined as blood pressure readings of >200/>110 mm Hg. Only 95 of 13,389 patients in the treated group progressed compared to 1,493 of 13,342 patients in the control or placebo groups.
Discussion
In a previous metaanalysis of 17 of the long-term hypertension treatment trials, we reported a statistically sign!ficant reduction of 38% in stroke mortality and 16% in coronary heart disease mortality (4). We had also previously reported a marked decrease in the number of patients reported to progress from less severe to severe hypertension in treated compared to Control subjects (6) . The present review concerns itself with an update on numbers of subjects who progressed from less severe to more severe degrees of hypertension, the prevention of left ventricular hypertrophy and the primary prevention of congestive heart failure. These data provide additional evidence of benefit from the treatment of hypertension.
When all of the hypertension treatment trials are reviewed, a marked reduction in the numbers of subjects who progressed to severe hypertension in treated compared to control or placebo subjects is noted. In addition, a large and highly significant decrease of 35% and 52%, respectively, was found in the occurrence of left ventricular hypertrophy and in the incidence of congestive heart failure in treated compared to control or placebo patients. These results should be factored into any "benefit of treatment" analysis. Pooling of data in a review of this type may pose difficulties if there are negative or equivocal studies that are combined with more positive ones. However, in this analysis of progression to more severe disease, left ventricular hypertrophy and congestive heart failure, data are highly consistent in all studies and all population groups (except for the lack of difference in the Australian Trial in Mild Hypertension) despite differences in demographic characteristics and possible differences in criteria for the diagnosis of congestive heart failure. Statistical errors are much less likely to occur in studies where results all move in the same direction.
Regression of left ventricnlar hypertrophy. This is another factor that should also be considered in estimating benefit of treatment of hypertension. It is well known that the treatment of hypertension will cause regression of both left ventricular mass and wall thickness. The long-term use of any of the available effective antihypertensive drugs, with the exception of the direct vasodilators, will result in regression of left ventricular hypertrophy (23) . A recent metaanalysis suggested that angiotensin-converting enzyme inhibitors were most effective in causing regression, with diuretics, beta-blockers and calcium antagonists somewhat less effective. However, many of the studies included in this metaanalysis were of short duration or included small numbers of subjects (24) . In two recent placebocontrolled studies (25, 26) , left ventricle mass and wall thickness decreased to the greatest extent with diuretics when compared with other classes of drugs, including angiotensinconverting enzyme inhibitors, beta-blockers, alpha-blockers and calcium channel blockers. In the diuretic-based SHEP study (19) , a statistically significant reduction in left ventricle mass was noted in treated compared to placebo subjects. In addition, in many other long-term trials, either ECG or echocardiographic evidence of regression of left ventricular hypertrophy has been reported to occur more often in treated than in placebo or control subjects. It is reasonable to assume that the regression of left ventricular hypertrophy is largely the result of blood pressure reduction, although some investigators believe that other factors may be of importance (27) . Despite concerns that the decrease in left ventricular muscle mass might be deleterious, cardiac function is not adversely affected in patients whose left ventricular hypertrophy has regressed. Because left ventricular hypertrophy most often precedes congestive heart failure in hypertensive individuals, the prevention of left ventricular hypertrophy or a decrease in left ventricle muscle mass as well as wall stress in subjects with pretreatment left ventricular hypertrophy is most probably the major reason for the decrease in the occurrence of congestive heart failure with blood pressure lowering. As noted in the treatment trials from which data were available, there was a highly significant decrease of 35% in the occurrence of left ventricular hypertrophy in treated compared to control or placebo subjects.
Effects of specific medications on prevention of congestive heart failure. It is clear that the treatment of hypertension, primarily with diuretics alone or in combination with antiadrenergic agents including beta-adrenergic inhibitors, results in the primary prevention of congestive heart failure; congestive heart failure is rare in hypertensive individuals whose blood pressures have been well controlled and who have not sustained a myocardial infarction. None of the long-term trials used other antihypertensive agents. Although it is possible that similar results will be obtained with the angiotensin-converting enzyme inhibitors or calcium channel blockers, we must await the results of several ongoing studies before we can conclude that equivalent results can be obtained with these medications.
